Author

P. W. Lewis

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:ChIP-seq· 2 Research Focus:chromatin & epigenetic regulation· 2 Assay:DNA methylation· 2 Approach:experimental assay· 2 Approach:biophysical modeling· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

A. Q. Rashoff· 2 shared N. Jabado· 2 shared N. Juretic· 2 shared S. Deshmukh· 2 shared S. U. Jain· 2 shared T. J. Do· 2 shared A. Bajic· 1 shared A. S. Harutyunyan· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 34 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Q. Rashoff

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Methylation of histone H3 lysine 36 is a barrier for therapeutic interventions of head and neck squamous cell carcinoma.

L. Caeiro, Y. Nakata, R. L. Borges, L. Garcia-Martinez, C. Banuelos, S. Stransky, H. L. Chan, J. Brabson, D. Dominguez, Y. Zhang, P. W. Lewis, S. A. Benitah, L. Cimmino, D. Bilbao, S. Sidoli, , L. Morey

This study shows that H3K36M mutations in HNSCC create a therapeutic window by altering H3K27me3 levels, making tumors sensitive to PARP1/2 inhibitors or their combination with H3K27me3-upregulating agents.

bioRxiv · Nov 6, 2023Cancer Biology

H3 K27M and EZHIP impede H3K27-methylation spreading by inhibiting allosterically stimulated PRC2

S. U. Jain, A. Q. Rashoff, S. D. Krabbenhoft, D. Hoelper, T. J. Do, T. J. Gibson, S. M. Lundgren, E. R. Bondra, S. Deshmukh, A. S. Harutyunyan, N. Juretic, N. Jabado, M. Harrison, P. W. Lewis

This study shows H3 K27M and EZHIP inhibit PRC2 activity by binding its allosterically activated form, reducing H3K27me3 levels but preserving it at CpG islands.

bioRxiv · Aug 5, 2020Cancer Biology

PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism

S. U. Jain, T. J. Do, P. J. Lund, A. Q. Rashoff, M. Cieslik, K. L. Diehl, A. Bajic, N. Juretic, S. Deshmukh, S. Venneti, T. W. Muir, B. A. Garcia, N. Jabado, P. W. Lewis

This study identifies EZHIP as a PRC2 inhibitor in PFA ependymomas that mimics the H3 K27M oncohistone by disrupting PRC2 activity and H3K27me3 levels.

bioRxiv · Mar 22, 2019Cancer Biology